Get the Stockscreener App
161.78
1.91%
3.03
After Hours:
161.78
Axsome Therapeutics Inc stock is traded at $161.78, with a volume of 432.93K.
It is up +1.91% in the last 24 hours and down -1.49% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$158.75
Open:
$160.74
24h Volume:
432.93K
Relative Volume:
0.64
Market Cap:
$8.28B
Revenue:
$638.50M
Net Income/Loss:
$-183.17M
P/E Ratio:
-43.79
EPS:
-3.6943
Net Cash Flow:
$-93.89M
1W Performance:
+2.48%
1M Performance:
-1.49%
6M Performance:
+39.45%
1Y Performance:
+34.41%
1-Day Range:
$160.60
$163.48
1-Week Range:
$152.28
$163.48
52-Week Range:
$86.99
$191.50
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
161.78 | 8.12B | 638.50M | -183.17M | -93.89M | -3.6943 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
Guggenheim Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome Therapeutics, Inc. $AXSM Position Increased by Assenagon Asset Management S.A. - MarketBeat
Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight - Barchart
JPMorgan Chase & Co. Has $30.43 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Market Overview: Is Axsome Therapeutics Inc stock trending bullishTrade Exit Report & Fast Gain Swing Trade Alerts - baoquankhu1.vn
AXSM PE Ratio & Valuation, Is AXSM Overvalued - Intellectia AI
Mizuho reiterates Axsome stock Outperform on Auvelity growth By Investing.com - Investing.com Canada
Analysts Are Bullish on Top Healthcare Stocks: PolyPid (PYPD), Axsome Therapeutics (AXSM) - The Globe and Mail
Axsome Therapeutics’ Q4 numbers beat Wall Street expectations: Analyst sees over 23% upside for stock - MSN
Superstring Capital's New Axsome Therapeutics Position: A $6.84M Biopharma InvestmentNews and Statistics - IndexBox
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain - AOL.com
Wolfe Research initiates coverage of Axsome Therapeutics (AXSM) with outperform recommendation - MSN
Axsome shares slip despite fourth-quarter earnings beat and strong revenue growth - MSN
(AXSM) Risk Channels and Responsive Allocation - Stock Traders Daily
Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision - AOL.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Purchased by Eventide Asset Management LLC - MarketBeat
A Look At Axsome Therapeutics (AXSM) Valuation As Legal Probe And FDA Decision Draw Investor Focus - simplywall.st
Profit Review: How much upside does Axsome Therapeutics Inc have2026 Outlook & Precise Swing Trade Entry Alerts - baoquankhu1.vn
AXSM's 2025 Revenue Growth Primarily Fueled by Auvelity: What Does the Future Hold? - Bitget
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead? - TradingView
RBC Capital reiterates Axsome Therapeutics stock rating at Outperform By Investing.com - Investing.com Canada
Axsome Therapeutics Highlights Auvelity’s $500M+ Run, FDA Catalyst and Late-Stage Pipeline at Conference - MarketBeat
Is It Time To Revisit Axsome Therapeutics (AXSM) After Recent Share Price Weakness - simplywall.st
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Axsome Therapeutics at The Citizens Life Sciences Conference: Strategic Growth Plans - Investing.com Canada
AXSM: Major 2026 catalysts include Auvelity's PDUFA for Alzheimer's agitation and field force expansion - TradingView
AXSM: April 2026 PDUFA for Auvelity in Alzheimer's agitation is a key near-term catalyst - TradingView
A Look At Axsome Therapeutics (AXSM) Valuation After Priority Review And 2025 Revenue Growth - Yahoo Finance
2 Under-the-Radar Stocks to Buy and Hold - The Globe and Mail
Axsome Therapeutics Highlights Auvelity Sales Push, April 30 PDUFA, and Symbravo Launch Updates - MarketBeat
Inceptionr LLC Invests $1.05 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics at Leerink Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
AXSM: Auvelity accelerates growth and pipeline advances with major expansions and new clinical programs - TradingView
Axsome Therapeutics, Inc. $AXSM is Rhenman & Partners Asset Management AB's 8th Largest Position - MarketBeat
(AXSM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Axsome Therapeutics, Inc. $AXSM Shares Sold by Quantbot Technologies LP - MarketBeat
Axsome Therapeutics touts AUVELITY $155M quarter, doubles salesforce ahead of April FDA decision - MarketBeat
Royce & Associates LP Raises Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Sold by Intech Investment Management LLC - MarketBeat
Assessing Axsome Therapeutics (AXSM) Valuation After Earnings Momentum And New Phase 3 Trial Launch - simplywall.st
AXSM Earnings History & Surprises | EPS & Revenue Results | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome Therapeutics, Inc. $AXSM Position Boosted by TD Asset Management Inc - MarketBeat
Should Axsome’s Revenue Jump and SUNOSI IP Win Require Action From Axsome Therapeutics (AXSM) Investors? - simplywall.st
AXSM: Robust late-stage pipeline and sales force expansion drive growth across CNS and pain markets - TradingView
AXSM: AUVELITY and pipeline assets drive growth, with key FDA decisions and launches ahead - TradingView
Axsome Therapeutics (AXSM): Analyst Consensus Highlights 35% Potential Upside for This Biotech Innovator - DirectorsTalk Interviews
Axsome Therapeutics Aktie: Wachstumskurs bestätigt - sharewise.com
DNB Asset Management AS Increases Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Bought by JPMorgan Chase & Co. - MarketBeat
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):